A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " JOINN Laboratories (China) Co., Ltd.

JOINN Laboratories (China) Co., Ltd.

JOINN Laboratories (China) Co., Ltd. is a leading China-based global contract research organization (CRO) providing integrated non-clinical research services across its own facilities. The company offers end-to-end support ranging from non-clinical studies, safety assessment, and disease model development to IND-enabling and regulatory submission support.
This section outlines the key features of JOINN Laboratories (China) Co., Ltd.’ non-clinical services, examples of disease models, and available case information.

Features of JOINN Laboratories (China) Co., Ltd.’ Contract Services for Non-Clinical Studies

High-quality material manufacturing using GMP-compliant bioreactor facilities

JOINN Laboratories (China) Co., Ltd. provides high-quality material manufacturing services utilizing GMP (Good Manufacturing Practice)-compliant bioreactor systems.Upstream processing capabilities include stainless steel bioreactors with volumes of up to 1,000 L, as well as single-use bioreactors with capacities of up to 500 L, enabling flexible optimization of cell culture processes.
These facilities support the production of preclinical materials as well as biologics and antibody therapeutics intended for clinical development, allowing JOINN to accommodate a wide range of client development needs. In combination with integrated in-process testing technologies, the company ensures robust process control and generates reliable, high-quality data.

Comprehensive IND registration and submission support

JOINN Laboratories (China) Co., Ltd.comprehensive support for Investigational New Drug (IND) registration and submission,aligned with regulatory requirements across multiple regions, including China (NMPA), the United States (FDA), and Japan (PMDA). Services cover the preparation of regulatory documentation from the non-clinical stage onward, including compilation of pharmacology and toxicology data, as well as development of clinical trial protocols and informed consent documents.
Dedicated regulatory teams develop submission strategies tailored to the specific characteristics of each compound and its development stage, streamlining the regulatory process, reducing time to approval, and enabling clients to efficiently prepare for global clinical trial initiation.

Evaluation systems compliant with international regulatory standards

JOINN Laboratories (China) Co., Ltd. conducts a broad range of safety studies in compliance with international standards, including FDA, ICH, and GLP requirements.Available studies include safety pharmacology, general toxicity, genotoxicity, and pathology assessments, as well as system-specific safety evaluations targeting cardiovascular, respiratory, and central nervous systems.
All studies are performed under standardized quality control systems, generating high-reliability data suitable for regulatory submission. Through comprehensive safety profiling and rigorous risk assessment, JOINN supports informed decision-making from the early stages of drug development.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Disease Models Available at JOINN Laboratories (China) Co., Ltd.

JOINN Laboratories (China) Co., Ltd. offersmetabolic disease models, including diet-induced obesity (DIO) models and type 2 diabetes models, for the establishment and evaluation of disease-relevant pathophysiology.In DIO models, animals such as mice fed a high-fat diet are used to reproduce human obesity and associated conditions, including insulin resistance and dysregulated lipid metabolism. Disease-related endpoints such as body weight gain, blood glucose fluctuations, and lipid profile changes can be assessed, supporting efficacy and safety evaluation of drug candidates as well as mechanistic studies.

In the field of infectious diseases,JOINN Laboratories (China) Co., Ltd. also providesanimal models, including influenza virus infection models.These models enable evaluation of antiviral efficacy, immune responses, and safety profiles of candidate therapeutics and vaccines in virus-infected animals, generating data that support drug discovery and development for infectious disease treatment and prevention.

JOINN Laboratories (China) Co., Ltd. Non-Clinical Case Study

No public nonclinical case examples are currently disclosed.

JOINN Laboratories (China) Co., Ltd. Company Information

Address	No. 5 Jia, Rongjing East Street, Economic and Technological Development Zone, Beijing, China (Beijing Head Office)
Tel	+86-10-67869966
Website	https://www.joinnlabs.com/en/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us